Earnings Frenzy! Pre-Market Movers You Can't Ignore!

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


Don't Let Politicians Get Away With Their Unfair Advantage

For decades, American politicians have been profiting from their insider knowledge.

And they're pretty good at it. One politician earned up to 238.9% on his investments last year. And scores of other politicians used their insider info to beat the market by a wide margin.

You can either complain or you can follow the money flow. The Freeport Society has used data from public filings from politicians to build a list of the 99 stocks political insiders are buying before the 2024 presidential election.

Access the free report here.

Happening Today

✓ 10:00 AM ET – JOLTs Job Openings (Feb)

✓ 10:00 AM ET – Factory Orders (MoM) (Feb)

✓ 10:10 AM ET – FOMC Member Bowman Speaks

✓ 12:00 PM ET – FOMC Member Williams Speaks


NASDAQ 100 leads the pack with a gain of 0.21%, while S&P 500 and Dow Jones track downward.



⬇️ -0.20% 



⬇️ -0.60%



⬆️ 0.21%


The market painted a predominantly red picture today, with all but two sectors experiencing losses. Consumer discretionary (-0.61%) and consumer staples (-0.77%) led the decline, reflecting cautious investor sentiment.




Consumer Discretionary


-0.61% 🔴

Consumer Staples


-0.77% 🔴



+0.79% 🟢



-0.63% 🔴

Health Care


-0.88% 🔴



-0.79% 🔴



-0.25% 🔴

Real Estate


-1.77% 🔴

Information Technology


+0.23% 🟢

Communication Services


+1.45% 🟢



-0.64% 🔴


9,530x the last time this happened

The last of three historically bullish crypto events is expected to happen around April 14.

It's only the fourth time in crypto history.

The last time, in 2020, certain altcoins exploded.

Some as high as 531,735% or even a 953,018% gain.

A tiny $100 investment would have returned just short of a million dollars.

Here's what our expert says you should buy before April 14.

Unusual Volume

📈 Sunshine Biopharma Inc (SBFM) jumped 76.03% to $0.11 on a whopping 294.15 million shares traded after it announced operating results for the fiscal year ended December 31, 2023.

📈 Investors went wild, sending CXApp Inc (CXAI) stock soaring 151.02% to $6.15 on a massive volume of 239.76 million shares after announcing partnership with Google Cloud for acceleration of deployment of CXAI Platform.

📈 Abnormal activity shook Gamida Cell Ltd (GMDA), pushing it up 3.32% to $0.04 on a whopping 51.78 million shares traded.

📈 MediaCo Holding Inc (MDIA) stock recently closed 53.37% upper at $0.81 on substantial volume of 22.44 million shares.

📈 Greenwave Technology Solutions Inc (GWAV) increase by 21.49% in a single trading session, with abnormally high trading volume of 22.19 million shares after the company declared that it has increased its shareholder's equity by approximately $14.87 million.


Stock Market Legend Shares Biggest Prediction Ever:

AI Phase 2 Will Mint More Millionaires Than Any Other Tech in HISTORY.

And I've Found the #1 Stock You NEED to Buy Right Now to Collect the Biggest Profits From This Once-in-a-Lifetime Market Shift.

Click Here to See

Premarket Movers

Trio Petroleum Corp. (TPET) experiences a substantial 146.75% surge in pre-market trading after filing of 8-K form with the SEC.

Anghami Inc. (ANGH) sees a significant 12.32% increase, reaching a pre-market price of $2.19 after the company announced successful completion of their landmark transaction after receiving all regulatory approvals.

Kidpik Corp. (PIK) demonstrates a noteworthy 44.14% surge, with a pre-market price of $6.27. The company announced a definitive merger agreement with Nina Footwear.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































$50 trade to make today with huge potential!

My favorite trade is an overnight options trade with just $50 or so bucks. I look for a precise setup that has delivered 300%+ gains overnight in the past. I'll show this trade for free in my brand-new presentation I just released. These overnight trades are a ton of fun to put on, easy to do on the side, and you close them fast. The next trade comes out on Thursday.

Click here to access my #1 options strategy for overnight wins starting with $50!

Important FDA 

Recently Announced

On March 25th, 2024, Regeneron (REGN) received an FDA rejection for odronextamab (R/R lymphoma) due to incomplete enrollment data.

Meanwhile, Esperion Therapeutics (ESPR) celebrated positive FDA news on March 22nd, 2024 with expanded approval for NEXLETOL/NEXLIZET in cardiovascular disease prevention.

Announcing Today

VNDAVANDA PHARMACEUTICALS (VNDA) is seeking approval from the FDA for an expanded use of Fanapt to treat bipolar I disorder in adults. The regulatory decision is still pending. Fanapt has already been approved in other countries for this use.

Upcoming Announcements

Supernus Pharmaceuticals, Inc. (SUPN) is awaiting an FDA decision on SPN-830 on April 5, 2024. SPN-830 is being evaluated for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease. The outcome of the FDA decision is currently pending.

Johnson & Johnson (JNJ) is also awaiting an FDA decision on April 5, 2024. Their drug Carvykti (sBLA) is under evaluation for an expanded use to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The final decision from the FDA is still pending.

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.